Please login to the form below

Not currently logged in
Email:
Password:

Boehringer bolts on another immuno-oncology company

Acquires ViraTherapeutics in a €210m takeover deal

BI

Boehringer Ingelheim’s shopping spree in immuno-oncology has continued with a €210m takeover of ViraTherapeutics, an oncolytic virus specialist it has been working with since 2016.

The privately-held German drugmaker must have been impressed with ViraTherapeutics’ lead candidate VSV-GP, a cancer therapy that works by infecting tumours with a virus that both destroys malignant cells directly and mobilises an immune response against them.

The original terms of the collaboration gave Boehringer an option to buy the company after phase I trials had been completed, but it’s taken the leap while VSV-GP is still in preclinical development. The drugmaker says the viral therapy has shown promising results in combination with its other immuno-oncology programmes.

“Our approach is rooted in transforming ‘cold’ tumours – or immunologically inactive tumours that are not responsive to the checkpoint blockers – to ‘hot‘ tumours – those that are most susceptible to immune system attack,” said Michel Pairet, Boehringer’s head of R&D.

“We are committed to investing in early research with promise and where our expertise best complements the strengths of our partners.”

ViraTherapeutics is just one a of a series of investments Boehringer has made in immuno-oncology, coming after a €1.1bn deal to license a checkpoint inhibitor from French biotech OSE Immunotherapeutics and earlier alliances with Siamab, AbeXXa Biologics, CureVac and Philogen.

The company currently has clinical-phase projects ranging across checkpoint inhibitors, oncolytic viruses, cancer vaccines and T-cell engagers, with around half of its early-to-mid-stage pipeline emerging from collaborations.

“Using a dual approach for potential treatment options, specifically combining immuno-oncology approaches with tumour cell-directed treatments, is central to Boehringer Ingelheim’s cancer immunology research strategy,” said the company in a statement. “Oncolytic virus-based therapies are consistent with and complement that strategy.”

The first oncolytic virus therapy to reach western markets was Amgen’s Imlygic (talimogene laherparepvec or T-Vec) which was approved by the FDA for melanoma in 2015. The first commercial use of this type of therapy was in China, however, after Shanghai Sunway Biotech got a green light for its H101 therapy for head and neck cancer in 2006.

Other oncolytic virus candidates coming through the development pipelines from the likes of Viralytics, Oncolytics Biotech, AstraZeneca/Omnis and Genelux.

Article by
Phil Taylor

13th September 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

David Atkins
A snapshot of Congenica
PME talks to CEO David Atkins...
Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...

Infographics